Anton Uvarov

Co-Founder, Executive Director

2021 - Current

https://blinklab.org/ BlinkLab founded in 2021 is a public company founded using technology developed at Princeton University. The company is developing software as a medical device, a mobile application that will be able to diagnose and monitor neurological disorders such as autism, ADHD, Rett Syndrome, Fragile X, etc using advanced facial recognition and AI/ML techniques. BlinkLab Ltd will be going public on Australian Securities Exchange in April 2024

Co-Founder, Director

2022

Co-Founder, Executive Director

2017 - 2022

ASX.NSB www.neuroscientific.com NeuroScientific Biopharmaceuticals is an Australian company listed on Australian Securities Exchange and is developing novel peptide-based pharmaceutical products that target a number of neurological disorders that have high unmet medical needs. The lead candidate EmtinB, a dendrimer molecule derived from Metallothionein is currently completing pre-clinical safety and toxicology program and multiple pre-clinical efficacy studies with first clinical trials to be initiated in 2022.

Director

2020 - 2022

ASX.NGS https://www.ngsolutions.co/ https://www.healthy-height.com/ NGS manufactures a unique formula-based protein powder for children aged three to nine that is consumed in beverages or smoothies. The product grew out of research by clinicians at Israel’s Schneider Children’s Medical Centre into ways that nutrition can be used to boost the height of young people. Following the clinical studies, NGS has sealed licensing deals for its protein powder in India. At first NGS had a licensing deal for its Healthy Height powder in India with GlaxoSmithKline, which later sold the business to Unilever, and the product is sold under the Horlicks brand. We currently distribute our brands globally, marketing throughout the USA, Asia, and the Middle East.

Director

2017 - 2018

ASX.PRZ www.parazero.com /Acquired by Delta Drones/ ParaZero specializes in the design, development and manufacturing of drone safety solutions for commercial drones. Our SafeAir safety box independently monitors the flight operation of the drone which in case of drone failure, triggers a patented ballistic parachute to provide a controlled descent rate, warns bystanders underneath and communicates with the UTM (Unmanned Traffic System).

Director

2016 - 2018

ASX.ELS www.el-sight.com Elsight is a solution provider of ground-breaking hybrid (on-the-move or fixed) video/data capturing, recording and transmission for various real- tactical security and surveillance purposes/applications that are crucial to the effective operations of security solutions, assuring improved detection, verification, investigation and tactical operations. Elsight's portfolio consist of broad variety of products including wearable and portable devices, vehicle mounted devices and fixed wall/fence mounting device (for various safe city and sensitive facilities management and surveillance ) - all controlled by Elsight's feature-reach C4i/Command & Control software for video/data monitoring, dispatching and recording.

Director

2016 - 2017

ASX.HMO http://home.hearmeoutapp.com/ HearMeOut is the leading voice-based social network where you can share your voice and listen to what others have to say. HearMeOut also introduces social communicating in your private car by creating the first social radio of its kind. By connecting to the vehicle’s systems and API’s, drivers can listen and record posts while driving via voice control features. They can also share posts on Facebook and Twitter without taking their eyes off the road. We are currently working with top car manufacturers and are about to implement our platform as part of the multimedia systems in various vehicles.

Director

2013 - 2017

ASX.ACW http://www.actinogen.com.au/ Actinogen Medical is a clinical stage biotechnology company listed on Australian Securities Exchange that is focused on the development of novel treatments for Alzheimer’s Disease and other major age-related neurodegenerative disorders. Company’s lead candidate Xanamem is a small molecule inhibitor of 11-beta-hydroxysteroid dehydrogenase (11β-HSD1) that is involved in cortisol metabolism. Xanamem has potential advantages as a drug for Alzheimer’s disease, including: high penetration into brain; low toxicity at therapeutic doses; potential for disease modification (reduction in amyloid plaque burden in pre-clinical studies); symptomatic effects that are independent of any disease-modifying effect; as well as an added potential for metabolic and cardiovascular risk factor reduction. Actinogen Medical is currently conducting a 200 patients Phase II efficacy study in patients with early Alzheimer's. https://clinicaltrials.gov/ct2/show/NCT02727699

Advisor

2013 - 2017

Forrest Capital provides corporate advisory, equity placement and underwriting services. Our clients are typically small to medium size Australian companies in life sciences and technology sectors seeking to undertake corporate transactions. The firm’s strategy is driven by research and supported by knowledge networks that include Industry Executives, Key Opinion Leaders, Fund Managers and Academic Institutions.

Advisor

2013 - 2017

Albion Capital Partners Pty Ltd is an Australian based specialist corporate advisory and investment company. Albion Capital has successfully arranged funding and sourced projects for a number of public companies in Australia and overseas in the fields of Technology, Telecommunications, Healthcare, Mining and Oil and Gas.

Director

2016 - 2016

ASX.IMU http://www.imugene.com/ Imugene is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Imugene’s lead product is HER-Vaxx, a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Her-Vaxx is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in a Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a known and validated cancer target. HER-Vaxx’s successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.